Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference


AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials for Pediatric Growth Hormone Deficiency (PGHD), announced that Lumos Pharma management will participate in a panel discussion and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference in October.

Read more here:
Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference

Related Posts